Cullinan Oncology launches new subsidiary focused on collagen-binding cytokine treatment
Cullinan Oncology operates as both a biotech and an investment fund, housing each of its assets in subsidiaries under one large umbrella. A little over a month after its last launch, Cullinan has announced another such project.
The Cambridge-based company introduced Cullinan Amber on Wednesday morning, the ninth drug development enterprise in its portfolio, and has obtained an exclusive license from MIT to utilize collagen binding technology. Thanks to this tech, Cullinan Amber’s lead program will combine two antitumor cytokines, IL-12 and IL-2, with a collagen-binding domain to produce what CMO Jon Wigginton hopes are more localized cancer treatments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.